share_log

TC BioPharm | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)

TC BioPharm | SC 13G/A:超过5%持股股东披露文件(修正)-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)

SEC announcement ·  02/14 14:39
Moomoo AI 已提取核心信息
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 105,938 American Depositary Shares of TC BioPharm (Holdings) PLC, which represents 9.99% of the class. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as the managing member of Armistice Capital, are deemed to beneficially own the shares held by the Master Fund. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing was certified by Steven Boyd on February 14, 2024.
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 105,938 American Depositary Shares of TC BioPharm (Holdings) PLC, which represents 9.99% of the class. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as the managing member of Armistice Capital, are deemed to beneficially own the shares held by the Master Fund. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing was certified by Steven Boyd on February 14, 2024.
2023年12月31日,停战资本有限责任公司和史蒂芬·博伊德向美国证券交易委员会提交了经修订的附表13G/A,表示对占该类别9.99%的TC BioPharm(控股)PLC的105,938股美国存托股票拥有共同的投票权和处置权。作为停战资本主基金有限公司投资经理的停战资本和作为停战资本管理成员的史蒂芬·博伊德被视为受益拥有主基金持有的股份。该文件是根据1934年《证券交易法》第13d-1(b)条提交的,表明股票是在正常业务过程中收购的,不是为了改变或影响发行人的控制权。该文件于2024年2月14日由史蒂芬·博伊德认证。
2023年12月31日,停战资本有限责任公司和史蒂芬·博伊德向美国证券交易委员会提交了经修订的附表13G/A,表示对占该类别9.99%的TC BioPharm(控股)PLC的105,938股美国存托股票拥有共同的投票权和处置权。作为停战资本主基金有限公司投资经理的停战资本和作为停战资本管理成员的史蒂芬·博伊德被视为受益拥有主基金持有的股份。该文件是根据1934年《证券交易法》第13d-1(b)条提交的,表明股票是在正常业务过程中收购的,不是为了改变或影响发行人的控制权。该文件于2024年2月14日由史蒂芬·博伊德认证。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息